Investigating the Effect of Reducing the Signs and Symptoms of Lid Wiper Epitheliopathy in Dry Eye Subjects with Perfluorohexyloctane

Current Therapeutic Research, Год журнала: 2025, Номер unknown, С. 100786 - 100786

Опубликована: Март 1, 2025

Язык: Английский

---

Synthetic Approaches to the New Drugs Approved during 2023

Journal of Medicinal Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Фев. 3, 2025

This review is the next installment of an annual series that discusses synthetic routes to access 28 small molecule drugs were approved worldwide in 2023. A brief description each drug's mechanism action, history its discovery and development, approaches published primary or patent literature most likely used for clinical studies development are included. Synthetic chemistry, convert complex intermediates active compounds build a new drug from basic building block chemicals, critical delivery treatments disease patients.

Язык: Английский

---

Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study

Ophthalmology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Фев. 22, 2025

Perfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms dry eye disease (DED) targets excessive tear evaporation. This study evaluated patient-reported outcomes early in with PFHO. prospective, multicenter, open-label, phase 4 enrolled adults a history DED ≥ 6 months. PFHO was instilled both eyes four times daily 14 days. Patients completed outcome surveys during clinic visits (day 1 [pretreatment; 5 60 min post-PFHO instillation] days 3, 7, 14). Symptom severity, symptom frequency, satisfaction were rated on visual analog scales (range 0–100). The primary endpoint mean change from baseline overall severity at day 7. Secondary endpoints included individual (eye dryness, blurred vision, irritation, light sensitivity, tiredness, burning/stinging, itching, pain); frequency (measured as percentage time experienced) most bothersome symptom, awareness symptoms, fluctuation quality vision; satisfaction. Ninety-nine patients (85.9% female; age range 35–81 years). met: (SD) decreased significantly 72.1 (17.0) to 27.8 (22.3) 7 (mean change, − 44.5; P < 0.0001). Mean experiencing 77.9% 34.7% (P Significant reductions also observed all postbaseline assessments Median ratings 83.0 86.0 90.0 14. Early course PFHO, experienced significant severity. Treatment high. ClinicalTrials.gov identifier NCT06309953.

Язык: Английский

---

In vitro biophysical and biological profiling of commercial lipid-based dry eye products

European Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер unknown, С. 107104 - 107104

Опубликована: Апрель 1, 2025

There is an increasing number of products available for treatment dry eye disease (DED), thereby creating a challenge in selecting suitable product. Commercial have rarely been studied the same experimental setup, and case lipid-based products, their baseline capabilities to target central defects DED requires more thorough investigation. This study aims discern potential differences abilities stabilize tear film, reduce evaporation water, impact on corneal epithelial cell viability recovery utilizing various biophysical biological vitro techniques. Seven commercial drops (Cationorm®, Desodrop®, Evotears®, Oxyal® Triple Action, PuroTM Suoja, Systane® Complete, Thealipid®) were selected profiling studies. Biophysical properties critical film stability reduction evaluated using Langmuir trough techniques, while assessed by MTT assay after exposing either healthy or damaged human cells products. The majority spread reasonably well at aqueous-air interface, suggesting that they bear intrinsic which may be beneficial improving coverage lipid layer. However, only subtle observed, indicating are not optimal targeting this defect. Clear with three being able promote cells. significance our findings regards outcomes will require additional

Язык: Английский

---

Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation

Advanced Science, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 28, 2024

Abstract The incidence of dry eye disease (DED) has been increasing annually worldwide, creating an urgent need for new therapies. Due to the multifactorial mechanism underlying DED, traditional medications focused on decreasing ocular surface inflammation have unable address all harmful factors and fail achieve a complete clinical cure. Ferroptosis, form programmed cell death characterized by lipid peroxidation, become pivotal contributor oxidative stress‐driven pathology. Therefore, therapeutic targeting ferroptosis may be attractive option management. Herein, sialic acid‐targeting peptide‐modified liposome loaded with Cyclosporine A (CsA), typical anti‐inflammatory drug, Ferrostatin‐1 (Fer‐1), selective inhibitor, is developed termed as CF@SNPs, combing sustaining DED treatment. This multifunctional liposomal encapsulation demonstrates excellent aqueous solubility; moreover, peptide prolongs retention, further enhancing efficacy. CF@SNPs treatment comprehensively alleviates symptoms, including improving corneal defects, augmenting goblet count, restoring tear secretion. Specifically, attenuate pathology suppressing p53‐SLC7A11‐GSH‐dependent TNF‐α‐associated inflammatory cascades, accompanied favorable biocompatibility in vivo. These results underscore promising potential this superior nano‐formulation pharmacotherapy.

Язык: Английский

---

Navigating dry eye relief: meibo’s approach to controlling tear evaporation

Annals of Medicine and Surgery, Год журнала: 2024, Номер 86(10), С. 5680 - 5684

Опубликована: Сен. 9, 2024

Язык: Английский

---

Meibomian gland lipid alterations and ocular surface sequela in Awat2 knockout murine model of meibomian gland dysfunction and evaporative dry eye disease

The Ocular Surface, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Язык: Английский

---